Idorsia Ltd (IDRSF) Stock Analysis

Idorsia Ltd (IDRSF) Healthcare & Pipeline Overview

Idorsia Ltd, a Swiss biopharmaceutical company, focuses on innovative drug development for CNS, cardiovascular, and immunological disorders. With a 90.5% gross margin, Idorsia collaborates with industry leaders like Janssen and Roche to advance its clinical pipeline and address significant unmet medical needs, while operating with a negative profit margin of -50.7%.

What Is the Investment Thesis for IDRSF?

Idorsia Ltd presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's focus on innovative drug development, particularly in CNS disorders and cardiovascular conditions, offers significant potential for growth. Key value drivers include the successful development and commercialization of its pipeline drugs, such as daridorexant for insomnia and aprocitentan for hypertension. The company's collaboration agreements with Janssen, Roche, and other pharmaceutical companies provide financial and strategic advantages. However, the company's negative P/E ratio of -6.70 and negative profit margin of -50.7% highlight the financial challenges associated with drug development. The high beta of 1.75 indicates significant volatility. Upcoming clinical trial results and regulatory approvals are critical catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

IDRSF Key Highlights

Market capitalization of $1.57B, reflecting investor valuation of Idorsia's pipeline and potential.

• Negative P/E ratio of -6.70, indicative of current losses but potential for future profitability upon successful drug commercialization.
• Gross margin of 90.5%, demonstrating strong pricing power on currently marketed products.
• Negative profit margin of -50.7%, highlighting significant R&D and operational expenses associated with drug development.
• Beta of 1.75, indicating higher volatility compared to the market, typical for biotechnology companies with developing pipelines.

Who Are IDRSF's Competitors?

IDRSF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are IDRSF's Key Strengths?

Innovative drug pipeline targeting unmet medical needs.

• Strategic collaborations with major pharmaceutical companies.
• Strong intellectual property protection.
• High gross margin on marketed products.

What Are IDRSF's Weaknesses?

Negative profit margin due to high R&D expenses.

• Reliance on partnerships for commercialization.
• Limited product portfolio currently on the market.
• High beta indicating significant stock volatility.

What Could Drive IDRSF Stock Higher?

Clinical trial results for ACT-709478 in epilepsy (Phase II).

• Regulatory approvals for Aprocitentan in hypertension.
• Expansion of Daridorexant market share for insomnia.
• Advancement of cancer immunotherapy collaboration with Roche.
• Development of Selatogrel self-administered drug device.

What Are the Key Risks for IDRSF?

Financial-distress signal — its Altman Z-Score of -12.00 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for pipeline drugs.
• Regulatory delays or non-approvals.
• Competition from established pharmaceutical companies.
• High R&D expenses impacting profitability.
• Dependence on partnerships for commercialization.

What Are the Growth Opportunities for IDRSF?

• Expansion of Daridorexant Market: Daridorexant, Idorsia's insomnia medication, represents a significant growth opportunity. The global insomnia market is projected to reach $5.1 billion by 2030, driven by increasing stress levels and sleep disorders. Idorsia's collaboration with Mochida Pharmaceutical for co-development and co-marketing in Japan could unlock substantial revenue streams. Successful market penetration and expansion into other geographies will be critical for realizing this potential. The timeline for significant revenue growth is estimated within the next 3-5 years.
• Aprocitentan Commercialization: Aprocitentan, developed in collaboration with Janssen Biotech, targets hypertension. The global hypertension market is estimated at $22 billion. Successful commercialization of aprocitentan could generate substantial revenue for Idorsia. The drug's novel mechanism of action and potential to address resistant hypertension offer a competitive advantage. Regulatory approvals and market launch are anticipated within the next 2-3 years, driving near-term growth.
• Advancement of ACT-709478: ACT-709478, in Phase II clinical trials for epilepsy, represents a key growth opportunity in the CNS therapeutic area. The global epilepsy market is projected to reach $10.7 billion by 2027. Positive clinical trial results and subsequent regulatory approval could position Idorsia as a significant player in this market. The timeline for potential commercialization is estimated within the next 3-5 years, contingent on successful trial outcomes.
• Development of Selatogrel: Idorsia's collaboration with Antares Pharma for a self-administered drug device product for Selatogrel targets acute cardiovascular events. The market for acute cardiovascular therapies is substantial, driven by the high incidence of heart attacks and strokes. A successful product launch could provide a significant revenue stream for Idorsia. The timeline for potential commercialization is estimated within the next 4-6 years, pending clinical trial results and regulatory approvals.
• Expansion into Cancer Immunotherapy: Idorsia's collaboration with Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy represents a long-term growth opportunity. The global cancer immunotherapy market is projected to reach $126.9 billion by 2030. This collaboration provides Idorsia with access to Roche's expertise and resources in oncology, potentially leading to the development of innovative cancer therapies. The timeline for significant revenue generation is estimated within the next 5-7 years, given the complexities of drug development in oncology.

What Are IDRSF's Competitive Advantages?

• Strong intellectual property portfolio protecting its drug candidates.
• Strategic collaborations with leading pharmaceutical companies, providing access to resources and expertise.
• Specialized expertise in drug discovery and development for specific therapeutic areas.
• Established clinical development pipeline with multiple drug candidates in various stages of development.

What Does IDRSF Do?

Idorsia Ltd, established in 2017 and headquartered in Allschwil, Switzerland, is a biopharmaceutical company dedicated to the discovery, development, and commercialization of novel medicines. The company focuses on addressing unmet medical needs across a range of therapeutic areas, including central nervous system (CNS) disorders, cardiovascular conditions, immunological disorders, and orphan diseases. Idorsia's pipeline includes a variety of clinical-stage compounds targeting these areas, reflecting its commitment to innovation and patient care. Idorsia has established strategic collaborations with several leading pharmaceutical companies to enhance its research and development efforts. These collaborations include a partnership with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and related compounds, focusing on hypertension. A licensing agreement with Mochida Pharmaceutical supports the supply, co-development, and co-marketing of daridorexant, a drug targeting insomnia. Additionally, Idorsia collaborates with Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy, expanding its reach into oncology. The company also partners with Antares Pharma, Inc. for a self-administered drug device product for Selatogrel and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478 for epilepsy treatment, currently in Phase II clinical trials. These partnerships are crucial for Idorsia's growth strategy, providing financial support, expertise, and access to broader markets.

What Products and Services Does IDRSF Offer?

• Discovers novel drug candidates targeting unmet medical needs.
• Develops pharmaceutical products for central nervous system (CNS) disorders.
• Creates treatments for cardiovascular conditions.
• Develops therapies for immunological disorders.
• Focuses on treatments for orphan diseases.
• Collaborates with pharmaceutical companies for drug development and commercialization.
• Conducts clinical trials to evaluate the safety and efficacy of drug candidates.

How Does IDRSF Make Money?

• Develops and patents novel pharmaceutical compounds.
• Out-licenses or co-develops drug candidates with larger pharmaceutical companies.
• Generates revenue through licensing fees, milestone payments, and royalties.
• Commercializes approved drugs directly or through partnerships.

What Industry Does IDRSF Operate In?

Idorsia Ltd operates in the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for CNS drugs, cardiovascular treatments, and immunotherapies is substantial and growing, driven by aging populations and increasing prevalence of chronic diseases. Competition includes established pharmaceutical giants and smaller biotech firms, all vying for market share with novel therapies. Idorsia's success depends on its ability to navigate the complex regulatory landscape, secure partnerships, and successfully commercialize its drug candidates. The biotechnology industry is seeing increased investment in innovative therapies, particularly in areas with unmet medical needs, creating both opportunities and challenges for companies like Idorsia.

Who Are IDRSF's Key Customers?

• Patients suffering from CNS disorders, such as insomnia and epilepsy.
• Patients with cardiovascular conditions, including hypertension.
• Healthcare providers who prescribe Idorsia's medications.
• Pharmaceutical companies that partner with Idorsia for drug development and commercialization.

Idorsia Ltd has beaten Wall Street's EPS estimate in 4 of its last 8 reported quarters — more hits than misses. Reported results have landed about 8.5% below estimates on average.

Idorsia Ltd's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.00 places it in the distress zone, a signal of elevated financial risk.

Return on equity for Idorsia Ltd stands at 19.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -45.9%, showing how much profit it generates from its asset base. Its free cash flow yield is -8.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.60 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -13.4%, the inverse of the P/E and a quick read on earnings relative to price.

Idorsia Ltd (IDRSF) Valuation Context

Valued at $1.57B, IDRSF is classified as a small-cap stock.

IDRSF Revenue & Earnings Trend

In Q2 FY2026, IDRSF generated $64.6M in top-line revenue, marking a sequential decrease of 8.2%. The company recorded a net loss of $131.2M, with diluted EPS of $-0.51. Quarter-over-quarter revenue has been mixed, typical for a small-cap company operating in Healthcare. Across the four most recent quarters, IDRSF averaged $-0.40 in diluted EPS.

Company Profile

Idorsia Ltd operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Allschwil, CH. The company is led by CEO Jean-Paul Clozel. IDRSF has traded publicly since 2017.

IDRSF Financials

IDRSF Latest News

IDRSF Analyst Consensus

IDRSF MoonshotScore

Common Questions About IDRSF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources